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Achieving Hemostasis With
Topical Hemostats: Making
Clinically and Economically
Appropriate Decisions in the
Surgical and Trauma Settings
MARTIN A. SCHREIBER, MD, FACS; DEBORAH J. NEVELEFFABSTRACT
Achieving hemostasis is a crucial focus of clinicians working in surgical and trauma
settings. Topical hemostatic agents—including mechanical hemostats, active hemostats,
flowable hemostats, and fibrin sealants—are frequently used in efforts to control bleed-
ing, and new options such as hemostatic dressings, initially used in combat situations, are
increasingly being used in civilian settings. To achieve successful hemostasis, a number
of vital factors must be considered by surgeons and perioperative nurses, such as the size
of the wound; bleeding severity; and the efficacy, possible adverse effects, and method
of application of potential hemostatic agents. Understanding how and when to use each
of the available hemostatic agents can greatly affect clinical outcomes and help to limit
the overall cost of treatment. AORN J 94 (November 2011) S4-S20. © AORN, Inc, 2011.
doi: 10.1016/j.aorn.2011.09.018
Key words: surgical bleeding, hemostasis, topical hemostatic agents, mechanical
hemostats, active hemostats, flowable hemostats, fibrin sealants, hemostatic
dressings.i
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bUncontrolled bleeding in the surgical andtrauma settings frequently results in aconsiderable clinical and economic
impact—prevention of this occurrence is pivotal
to surgical success and positive patient outcomes.
If not managed properly, surgical bleeding can
extend the length of the surgical procedure and
necessitate blood transfusions; uncontrolled bleed-
ing also can impair wound healing and increase
the risk of infection and is associated with i
S4 AORN Journal ● November 2011 Vol 94 No 5ncreased mortality rates and higher costs of
are.1,2 Accordingly, achieving hemostasis, or
leeding control, is a crucial focus of clinicians
orking in surgical and trauma settings. Al-
hough this is clearly a major concern for sur-
eons, it is also an important consideration for
erioperative nurses, who play a vital role in
chieving hemostasis by monitoring surgical
leeding and suggesting, preparing, and apply-
ng appropriate hemostatic agents.
doi: 10.1016/j.aorn.2011.09.018
© AORN, Inc, 2011
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NACCME SUPPLEMENT www.aornjournal.orgTopical hemostatic agents—including mechani-
cal hemostats, active hemostats, flowable hemo-
stats, and fibrin sealants—are frequently used,
often in combination, in efforts to control bleed-
ing. Because timeliness is a crucial factor in
achieving hemostasis, it is paramount that the sur-
gical team use sound clinical judgment in select-
ing an agent or combination of agents to optimize
patient outcomes. Critical considerations in hemo-
stat selection include
 the size and configuration of the wound;
 bleeding severity; and
 the agent’s
 efficacy,
 possible adverse effects,
 method of application,
 ease of use,
 timing requirements, and
 storage specifications.
Given the wide variety of available agents, perioper-
ative nurses must be aware of their appropriate uses
and understand how to apply these agents safely and
effectively in various surgical settings.
THE CLINICAL AND ECONOMIC IMPACT
OF SURGICAL BLEEDING
Despite the availability of numerous hemostatic
agents, the prevalence and clinical burden of
hemorrhage remain considerable.3,4 Hemorrhage
is associated with approximately 37% of deaths
TABLE 1. Consequences of Bleeding1
Clinical consequences
 Hemodynamic instability
 Reduced oxygen delivery to the tissues
 Hypovolemia
 Anemia
 Increased risk of organ failure
 Increased morbidity and mortality risk
1. Zimmerman LH. Causes and consequences of critical bleeding and meafter trauma, including mortality in the field as aell as in the hospital setting.3 Furthermore, the
ast majority of preventable trauma-related deaths
re caused by hemorrhage. Given that 50% of
atients die within 12 hours of injury, achieving
rompt cessation of bleeding is critical to reduc-
ng trauma mortality rates.3 Clinical consequences
f bleeding also are significant and include hemo-
ynamic instability, reduced oxygen delivery to
ital tissues, hypovolemia, anemia, and increased
isk of organ failure (Table 1).4
Given these clinical implications, the economic
mpact of bleeding can be substantial, largely be-
ause of the increased use of hospital resources.4,5
he extent of bleeding often correlates directly with
he requirement for increased patient monitoring, the
eed for specialist consultations, and extended
ength of hospital stay.4 The requirement for an ex-
ended length of stay can be particularly costly, with
ostoperative inpatient care estimated at $1,280 per
ay, intensive care unit treatment approximated at
3,670 per day, and intensive care unit treatment
ith mechanical ventilation costing $4,810 per day.5
edical interventions requiring use of transfusions
an range from $1,840 to $2,760 per unit.4,5 Fur-
hermore, uncontrolled bleeding often requires surgi-
al intervention, resulting in longer procedure times,
return to the OR, or both.4 With time in the OR
anging between $1,890 and $3,150 per hour, the
ost of treatment, if not properly managed, can
uickly escalate and, in some instances—such as
Economic consequences
 Surgical intervention
 Increased procedure time, return to OR
 Medical therapeutic intervention
 Blood products
 Systemic and topical hemostats
 Monitoring
 Specialist consult
 Increased length of hospital stay
s of blood coagulation. Pharmacotherapy. 2007;27(9 Pt 2):45S-56S.chanismrepeat surgery for bleeding after cardiac
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November 2011 Vol 94 No 5 SCHREIBER—NEVELEFFsurgery—can total as much as $30,000.5 Under-
standing how and when to use each of the avail-
able hemostats can, therefore, greatly affect not
only clinical outcomes, but also help to limit the
overall cost of treatment.
THE COAGULATION CASCADE
Prompted by injury to a blood vessel, the coagula-
tion cascade—the mechanism by which both the
body’s natural response and hemostatic agents con-
trol bleeding—is a complex physiologic process that
involves multiple interactions and coagulation fac-
tors (Figure 1).6 The coagulation cascade initially
involves two pathways: an intrinsic pathway mea-
sured by prothrombin time and an extrinsic pathway
analyzed by the partial thromboplastin time.6 These
pathways converge into a common pathway, where
prothrombin is cleaved, producing thrombin.6
Thrombin is the central activator in all clot forma-
tion; it is necessary to cleave fibrinogen into fibrin b
S6 AORN Journalnd for the activation of factor V and factor VIII.
hrombin is also needed at the bleeding site for
ocal hemostasis, and it plays a pivotal role in plate-
et plug and fibrin formation.6
LASSIFICATION OF TOPICAL
EMOSTATIC AGENTS
opical hemostatic agents can be classified into
our general categories based on their primary
omponents.5,7 Mechanical hemostats—including
orcine gelatin, cellulose, bovine collagen, and
olysaccharide spheres—activate the extrinsic
oagulation cascade and form a matrix at the
leeding site. Mechanical agents that include
hrombin also have an intrinsic clotting mecha-
ism.5,7 Agents such as bovine thrombin, human
ooled plasma thrombin, and recombinant throm-
in are classified as active hemostatic agents
ased on their reliance on thrombin to control
leeding.5,7 The third category of topical agents,
NACCME SUPPLEMENT www.aornjournal.orgSealants and Adhesives
Although fibrin sealants offer the benefit of hemostatic properties, nonfibrin sealants and adhesives
used in conjunction with hemostatic agents are equally vital to the surgical armamentarium in re-
ducing surgical bleeding and meeting related transfusion needs.1 An outline of available sealants
and adhesives—including administration information vital for consideration by perioperative nurses
in selecting the appropriate agent for a given surgical situation—is included below.
Polyethylene glycol (PEG) polymers
 Clinical considerations1
 Should be applied to as dry a field as possible
 Use caution to avoid liquid adhesive dripping to undesirable locations
 Available formulations1
 Coseal® (single PEG polymer)
 DuraSealTM (dual PEG polymer)
 ProGel® (biocompatible protein with PEG polymer)
Cyanoacrylates
 Clinical considerations1
 Should be used to avoid wound dehiscence associated with deep dermal sutures
 Allow for adhesive curing by keeping skin edges apposed for  20 seconds
 Use caution to avoid liquid adhesive dripping to undesirable locations
 Available formulations1
 Dermabond® (octyl cyanoacrylate)
 Histoacryl®/Histoacryl® Blue (butyl cyanoacrylate)
 Indermil® (butyl cyanoacrylate)
 Ethicon Omnex® (2-octyl cyanoacrylate and butyl lactoyl cyanoacrylate)
BioGlue® (bovine serum albumin and glutaraldehyde)
 Clinical considerations1
 Should be applied carefully and used as sparingly as possible because of the strong sealant
and adhesive properties
 When used, wall off critical zones of the surgical field with sponges or pads, thus prevent-
ing injury to nerves or vessels/arteries
Editor’s note: Coseal is a registered trademark of Baxter International, Inc, Deerfield, IL.
DuraSeal is a trademark of Confluent Surgical, Inc, Waltham, MA. ProGel is a registered trade-
mark of Neomend, Inc, Irvine, CA. Dermabond is a registered trademark of Johnson & Johnson,
New Brunswick, NJ. Histoacryl is a registered trademark of B. Braun Corp, Bethlehem, PA.
Indermil is a registered trademark of Henkel Corp, Düsseldorf, Germany. Ethicon Omnex is a reg-
istered trademark of Johnson & Johnson, New Brunswick, NJ. BioGlue is a registered trademark
of CryoLife, Inc, Kennesaw, GA.
1. Spotnitz WD, Burks S. State-of-the-art review: hemostats, sealants, and adhesives II: update as well as how and
when to use the components of the surgical toolbox. Clin Appl Thromb Hemost. 2010;16(5):497-514.AORN Journal S7
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November 2011 Vol 94 No 5 SCHREIBER—NEVELEFFknown as flowable hemostats, contain gelatin or a
gelatin matrix plus thrombin and are dispensed in
a paste-like, flowable structure from a syringe
directly into the wound to achieve hemostasis.5,7
The fibrinogen- and thrombin-containing fibrin
sealants represent the final category of hemostats;
these work by sealing tissue and are effective at
closing up blood vessels, lymphatics, biliary radi-
cals, and other sources of bleeding.5,7
A number of factors affect which category of
topical hemostat should be used to control bleed-
ing in a given clinical scenario. These factors in-
clude the size and configuration of the wound, the
severity of bleeding, the accessibility of the
bleeding site, the coagulation status of the patient,
and whether the bleeding has occurred during a
primary or secondary surgical procedure. Periop-
erative nurses can greatly affect clinical outcomes
by selecting hemostats based on the underlying
mechanism of action and with consideration for
individual patient circumstances (Table 2).8-19
Mechanical Hemostatic Agents
Mechanical hemostats—including porcine gelatin
(Gelfoam®, Gelfoam® Plus, Surgifoam®), cellu-
lose (Surgicel®, Surgicel Nu-Knit®), bovine col-
lagen (Avitene® sheets, UltrafoamTM collagen
sponges), and polysaccharide spheres (Arista®)—
integrate an absorbable sponge, foam, pad, or
other material with a topical hemostatic agent,
which is then applied to the affected area.7,8
These agents form a matrix at the site of bleed-
ing, activating the extrinsic clotting pathway,
which allows clotting to occur.7,8
Mechanical hemostats rely on fibrin production
to achieve hemostasis; therefore, these agents are
only appropriate for patients who have an intact
coagulation cascade.6 Patients with hemorrhage
secondary to a significant coagulopathy, for ex-
ample, would not be appropriate candidates for
this type of hemostatic treatment. Mechanical
agents accelerate the coagulation cascade, thereby
achieving hemostasis in a timely fashion.6 Despite
having a similar underlying mechanism of action, r
S8 AORN Journalhe efficacy of mechanical hemostats varies
mong products.6 Typically, the bovine collagen
roducts and polysaccharide spheres are consid-
red the most effective; porcine gelatins are noted
o have improved efficacy when combined with
opical thrombin.14 Mechanical hemostats are typ-
cally used as first-line agents because of their
mmediate availability and low associated costs.14
echanical hemostats are most useful in situa-
ions of minimal bleeding.14
ctive Hemostatic Agents
opical thrombins that stimulate fibrinogen at
he bleeding site to produce a fibrin clot are
nown as active hemostats.6 These agents can
e used effectively in patients with coagulation
ystems that are impaired as a result of heparin-
zation, mild coagulopathy, or other conditions.8
he active hemostats—namely bovine thrombin
Thrombin-JMI®),9 recombinant thrombin
Recothrom®),11 and pooled human plasma
hrombin (Evithrom®)10—are more effective
han mechanical hemostats at controlling local
leeding, although typically they are more costly.8
ctive hemostats can be applied via pump or
pray kits to evenly cover large wound areas or
elivered via a saturated, kneaded, absorbable
elatin sponge directly to the site of bleeding.8
Bovine thrombin is the most common and least
xpensive of the active hemostats used in the
nited States today.9 Often considered the “gold
tandard” of thrombin products because of its
onvenience and ease of use, bovine thrombin
s stored at room temperature and comes in a
owder form that can be reconstituted easily with
aline solution when needed for use.9 Derived
rom hamster ovarian cells, recombinant thrombin
s another commonly used topical thrombin that is
lso available in a powder that can be stored at
oom temperature.11 Bovine and recombinant
hrombin have equivalent efficacy; a phase 3,
ouble-blind comparative study in which 401 pa-
ients were randomly assigned to receive either
ecombinant or bovine thrombin showed that
TABLE 2. Reference Guide to Hemostatic Agents1-12
Type of agent Agents
Preparation and administration
considerations Mechanism of action Clinical indications
Mechanical agents Porcine gelatin
(Gelfoam®,
Gelfoam® Plus,
Surgifoam®)
 Available as sponge or powder
 Store at room temperature;
immediately available for use
 1-time use, not resterilizable
 Use alone or in combination with
saline or topical thrombin
 Provides matrix for clot
formation
 Creates a mechanical barrier
to bleeding
 When possible, remove after
hemostasis is achieved
 Typically used in cases of minimal bleeding
 Conforms to wounds; suitable for irregular
wounds
 Not to be used in infected fields or around
neural elements because of swelling risk
 Not for intravascular use
Cellulose (Surgicel®,
Surgicel Nu-Knit®)
 Available as single or multiple sheets
 Store at room temperature;
immediately available for use
 Not resterilizable
 Use dry, do not combine with topical
thrombin
 Excess can be removed with
irrigation
 Provides matrix for clot
formation
 When possible, remove after
hemostasis is achieved,
particularly in neurologic and
urologic surgery
 Suited for control of capillary, venous, and
small arterial bleeding
 Sheets can be cut into smaller pieces/strips
for suitable placement; smaller pieces can
be easily manipulated into place
 Not for use in closed spaces because
swelling can occur; not for use in bone
fracture
Bovine collagen
(Avitene® sheets,
UltrafoamTM
collagen sponges)
 Available as sheets, flours, or
sponges
 Store at room temperature;
immediately available for use
 Not resterilizable
 Use dry, do not combine with saline
or thrombin
 Excess can be removed with
irrigation
 Serves as a matrix for clot
formation and strengthening
 Enhances platelet
aggregation, degranulation,
and release of clotting factors
 Suited for control of capillary, venous, and
small arterial bleeding
 Sheets best used on flat surfaces or to
wrap vessels and anastomosis sites
 Not for use in closed cavities or areas that
may conflict with skin closure
 In ophthalmic or urologic surgery, use only
sponges
 Should not be used in combination with
blood salvage systems
Polysaccharide
spheres (Arista®)
 Available as powder in a bellows
applicator
 Flexible storage temperature (40.6°
C [41° F] to 60° C [140° F]);
immediately available for use
 Not resterilizable
 Excess can be removed with
irrigation
 Produces a hydrophilic effect
 Dehydrates blood
 Concentrates the solid
components of blood,
increasing barrier formation
 Suited for control of capillary, venous, and
small arterial bleeding
 Not for use in closed spaces because
swelling can occur
 Not to be used in neurologic, urologic, or
ophthalmic surgery
 Do not use  50 g in patients with diabetes
because spheres are composed of sugars
(continued)
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TABLE 2. (continued) Reference Guide to Hemostatic Agents1-12
Type of agent Agents
Preparation and administration
considerations Mechanism of action Clinical indications
Active hemostatic
agents
Bovine thrombin
(Thrombin-JMI®)
 Available as powder in vial form
 Store at room temperature
 Use dry or reconstitute with sterile
saline
 Use within 3 hours of reconstitution
 Apply via pump or spray kits or
deliver via saturated, kneaded,
absorbable gelatin sponge
 Actively converts fibrinogen to
fibrin, thereby resulting in
clotting
 Broad surgical use for minor bleeding from
accessible capillaries and small venules
 Presence of circulating fibrinogen is
necessary
 Contraindicated in patients with bovine
allergies
 Should not be used in patients who have
developed coagulopathy because of
previous exposure to bovine thrombin
Recombinant
thrombin
(Recothrom®)
 Available as lyophilized powder in vial
form
 Store at room temperature
 Reconstitute with sterile saline
 Use within 24 hours of reconstitution
 Apply via pump or spray kits or
delivered via saturated, kneaded,
absorbable gelatin sponge
 Actively converts fibrinogen to
fibrin, thereby resulting in
clotting
 Broad surgical use for minor bleeding from
accessible capillaries and small venules
 Presence of circulating fibrinogen is
necessary
 Should be used when control of bleeding
by standard surgical techniques is
ineffective or impractical
 Contraindicated in patients with
hypersensitivity to hamster and snake
proteins
 Should not be used in combination with blood
salvage or cardiopulmonary bypass systems
Pooled human
plasma thrombin
(Evithrom®)
 Available as frozen liquid in vial form
 Storage options: frozen (18° C
[40° F]) for 2 years, refrigerated (2°
C to 8° C [35.6° F to 46.4° F]) for 30
days, room temperature (20° C to
25° C [68° F to 77° F]) for 24 hours,
or 37° C (98.6° F) for 1 hour
 Use within 24 hours of reconstitution
 Deliver via saturated, kneaded,
absorbable gelatin sponge
 Actively converts fibrinogen to
fibrin, thereby resulting in
clotting
 Broad surgical use for minor bleeding from
accessible capillaries and small venules
 Presence of circulating fibrinogen is
necessary
 Should be used when control of bleeding
by standard surgical techniques is
ineffective or impractical
 Contraindicated in patients with human
blood product allergies
 Should not be used in combination with blood
salvage or cardiopulmonary bypass systems
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TABLE 2. (continued) Reference Guide to Hemostatic Agents1-12
Type of agent Agents
Preparation and administration
considerations Mechanism of action Clinical indications
Flowable hemostatic
agents
Surgiflo®  Powder, available as syringe with
connector to permit combination with
saline or thrombin
 Store at room temperature
 Preparation involves mixing gelatin
with thrombin
 Use completely mixed product within
8 hours
 Utilizes mechanisms of
human thrombin and porcine
gelatin
 Incorporates both mechanical
and active components to
achieve hemostasis
 Excess should be removed
because of possibility of
swelling
 Indicated for use in all surgical specialties
except urologic and ophthalmic surgery
 Should not be used in patients with porcine
allergies
 Suited for use in irregular wounds or
bleeding cavities
FloSeal®  Granular hemostat
 Store at room temperature
 3-minute reconstitution—reconstitute
thrombin (use within 4 hours), mix
thrombin with gelatin matrix
 Use completely mixed product within
2 hours
 Apply as paste with gentle pressure
from moist saline sponge
 May be reapplied with blunt
applicator tip if bleeding continues
 Utilizes mechanisms of
human thrombin and bovine
gelatin
 Incorporates both mechanical
and active components to
achieve hemostasis
 Excess should be removed
because of possibility of
swelling
 Indicated for use in all surgical specialties
except ophthalmic surgery
 Should not be used in combination with
blood salvage or cardiopulmonary bypass
systems
 Suited for use in irregular wounds or
bleeding cavities
Fibrin sealants Tisseel®  Available as freeze-dried or frozen
product
 Freeze-dried product can be stored
refrigerated or at room temperature
 Frozen product is premixed and can
be stored frozen or at room
temperature for up to 48 hours
 Product must be thawed in field
water bath or incubator (5 to 105
minutes to thaw)
 After thawed and reconstituted, use
within 4 hours
 Provides a source of
fibrinogen to site of injury
 Does not need active
bleeding to polymerize
 Indicated for use in cardiac and splenic
repair surgery as a topical hemostat
 Indicated for use in colostomy closure as a
sealant
 Should not be used in combination with
blood salvage or cardiopulmonary bypass
systems
 Delayed availability makes it less attractive
for emergent indications
(continued)
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TABLE 2. (continued) Reference Guide to Hemostatic Agents1-12
Type of agent Agents
Preparation and administration
considerations Mechanism of action Clinical indications
Evicel®  2 fully-mixed, frozen components—
biologically active fibrinogen and
thrombin
 Storage options: frozen (18° C
[40° F]) for 2 years, refrigerated (2°
C to 8° C [35.6° F to 46.4° F]) for 30
days, room temperature (20° C to
25° C [68° F to 77° F]) for 24 hours
 Thawing requires 1 day at 2° C to 8°
C (35.6° F to 46.4° F), 1 hour at room
temperature (20° C to 25° C [68° F to
77° F]), or no more than 10 minutes
in a water bath at no more than 37°
C (98.6° F)
 No mixing required—each
component is placed into the delivery
device and mixed on application
 Applied via applicator device
provided with or without gas-driven
source; tip can be cut back to avoid
clogging
 Provides a source of
fibrinogen to site of injury
 Does not need active
bleeding to polymerize
 Indicated for use in all surgical specialties,
particularly liver and vascular surgery
 Should not be used in combination with
blood salvage or cardiopulmonary bypass
systems
 Not indicated for treatment of severe or
brisk arterial bleeding
 Not for use in individuals with known
anaphylactic or severe systemic reaction to
human blood products
 Can be applied to broad surface area
bleeding
New dressings HemCon®  Bandages in various sizes
 Store at room temperature;
immediately available for use
 Apply directly to the site of bleeding
with firm, even pressure
 Bandage may be backed with gauze
to ensure uniform pressure and
increase performance
 Bandage can remain in place for as
long as 48 hours
 Adheres when in contact
with blood because of
mucoadhesive properties
 Forms a seal on the wound
and controls bleeding
 Fabricated from chitosan,
which attracts red blood cells
to create a seal over the
wound
 Remove with water or saline
 Indicated for the external temporary control
of severely bleeding wounds
 For use in the emergency setting
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TABLE 2. (continued) Reference Guide to Hemostatic Agents1-12
Type of agent Agents
Preparation and administration
considerations Mechanism of action Clinical indications
QuikClot Combat
Gauze®
 Nonwoven gauze with kaolin
 Store at room temperature;
immediately available for use
 Additional dressings may be applied;
however, the initial dressing should
not be removed because removal
may disrupt clot formation
 Bandage can remain in place for as
long as 24 hours
 Initiates clotting when in
contact with blood by
activating factor XII
 Pressure from gauze packing
compresses bleeding
 Fabricated from chitosan,
which attracts red blood cells
to create a seal over the
wound
 Remove with water or saline
 Indicated for temporary external use to
control traumatic bleeding
 For use in the emergency setting
Editor’s note: Gelfoam is a registered trademark of Pharmacia & Upjohn Company LLC, Peapack, NJ. Surgifoam is a registered trademark of Ferrosan Medical Devices A/S, Søborg, Denmark. Surgicel, Surgicel
Nu-Knit, Evithrom, Surgiflo, and Evicel are registered trademarks of Johnson & Johnson, New Brunswick, NJ. Avitene is a registered trademark and Ultrafoam is a trademark of C. R. Bard, Inc, Murray Hill, NJ.
Arista is a registered trademark of Medafor, Inc, Minneapolis, MN. Thrombin-JMI is a registered trademark of King Pharmaceuticals, Inc, Bristol, TN. Recothrom is a registered trademark of ZymoGenetics, Inc,
Seattle, WA. FloSeal and Tisseel are registered trademarks of Baxter International, Inc, Deerfield, IL. HemCon is a registered trademark of HemCon Medical Technologies, Inc, Tigard, OR. QuikClot Combat Gauze
is a registered trademark of Z-Medica Corp, Wallingford, CT.
1. Spotnitz WD, Burks S. Hemostats, sealants, and adhesives: components of the surgical toolbox. Transfusion. 2008;48(7):1502-1516.
2. Thrombin-JMI® [package insert]. Bristol, TN: King Pharmaceuticals, Inc; 2007.
3. Evithrom® [package insert]. Somerville, NJ: Ethicon, Inc; 2007.
4. Recothrom® [package insert]. Seattle, WA: ZymoGenetics, Inc; 2008.
5. Tisseel® [package insert]. Westlake Village, CA: Baxter Healthcare Corp; 2009.
6. Evicel® [package insert]. Somerville, NJ: Johnson & Johnson Wound Management; 2009.
7. Spotnitz WD, Burks S. State-of-the-art review: hemostats, sealants, and adhesives II: update as well as how and when to use the components of the surgical toolbox. Clin Appl Thromb Hemost. 2010;16(5):
497-514.
8. Surgiflo® hemostatic matrix kit [package insert]. Somerville, NJ: Ethicon, Inc; 2009.
9. FloSeal hemostatic matrix [package insert]. Fremont, CA: Baxter Healthcare Corp; 2005.
10. Samudrala S. Topical hemostatic agents in surgery: a surgeon’s perspective. AORN J. 2008;88(3):S2-S11.
11. The hemostatic HemCon® bandage. HemCon Medical Technologies, Inc. http://www.hemcon.com/products/hemconbandageoverview.aspx. Accessed September 14, 2011.
12. How QuikClot works. Z-Medica. http://www.z-medica.com/healthcare/How-QuikClot-Works/How-QuikClot-Works.aspx. Accessed September 14, 2011.
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November 2011 Vol 94 No 5 SCHREIBER—NEVELEFFhemostasis was achieved within 10 minutes in 95%
of both patient groups.20 Overall complications,
including mortality, adverse events, and labora-
tory abnormalities, also were similar between the
two groups.20 Pooled human thrombin—a human
plasma derivative that has similar efficacy to bo-
vine thrombin—comes in liquid form, as opposed
to a powder formulation; notably, this active he-
mostat requires refrigeration and is the most ex-
pensive topical thrombin product.10
Despite having similar efficacy, individual
thrombin products differ significantly in terms
of potential complications.9-11,20 Bovine throm-
bin can cause an immunologic reaction, primar-
ily related to factor V, which may not be evi-
dent until the patient is re-exposed to the
product.9 Therefore, a patient undergoing a sec-
ond or third vascular procedure may be at risk
for an immunologic reaction that can result in
severe immune-mediated coagulopathy.9 More-
over, in the phase 3 clinical trial cited previ-
ously, 21.5% of the patients receiving bovine
thrombin developed antibodies to the product,
whereas only 1.5% of patients receiving recom-
binant thrombin exhibited antibody formation
after administration (P  .0001).20 Recombi-
nant thrombins, however, have the potential to
cause an allergic reaction in patients who are
allergic to hamster or snake proteins, because
recombinant thrombins are produced using cells
from these animals.11 In addition, pooled hu-
man thrombin carries the risk of infection trans-
mission.10 Pooled human thrombin undergoes a
series of cleansing procedures during manufac-
turing, but the chance for transmission of viral
infection remains.10 Importantly, because of the
risk for major anaphylactic reaction and/or hy-
potension, none of the thrombin products are
approved for intravenous use.9-11 In the trauma
and surgical settings, it is essential that both
the surgeon and perioperative nursing staff be
mindful of which active hemostat is applied to
mitigate the risks associated with its use. .
S14 AORN Journallowable Hemostatic Agents
omposed of either a porcine or bovine gelatin
atrix plus thrombin, flowable hemostatic agents
eg, Surgiflo®, FloSeal®) are another important
ool for perioperative nurses, because they pro-
ide both a mechanical and an active hemostat in
single application to effectively control bleed-
ng.8 Surgiflo is a porcine gelatin that is used in
ombination with bovine or other thrombins.8
loSeal includes bovine gelatin microgranules
ombined with human pooled plasma thrombin
nd calcium chloride, a critical element for acti-
ation of coagulation in each step of the coagula-
ion cascade.8 Because human plasma thrombin
olidifies into a paste-like consistency when com-
ined with gelatin, both agents allow for more
ccurate administration compared with a liquid
hrombin alone.8 Additionally, FloSeal and Surgi-
o only require two to three minutes of prepara-
ion time and are applied using a syringe-like de-
ice, making them appropriate in the trauma
etting where timeliness is critical. These agents
re also ideal for treating patients who may have
small entry wound leading into a larger cavity,
uch as a gunshot wound.7,8
The safety and efficacy of flowable hemostatic
gents are well supported in the clinical litera-
ure.21,22 A prospective, randomized trial con-
ucted at four institutions compared the efficacy
f FloSeal with Gelfoam plus thrombin in con-
rolling intraoperative bleeding in patients under-
oing vascular surgery procedures.21 The re-
earchers reported that, at 10 minutes, more than
0% of FloSeal recipients had achieved hemosta-
is, compared with approximately 80% of
elfoam plus thrombin recipients (P  .001).21
n another multicenter trial, 93 patients undergo-
ng cardiac surgery were randomly assigned to
eceive either FloSeal or Gelfoam plus thrombin;
ithin 10 minutes of application, 94% of FloSeal
ecipients exhibited complete cessation of
leeding, whereas only 60% of Gelfoam plus
hrombin recipients achieved hemostasis (P 
001).22 Of patients with heavy bleeding, 77%
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NACCME SUPPLEMENT www.aornjournal.orgof those in the FloSeal group achieved hemo-
stasis at three minutes, compared with none of
the patients receiving Gelfoam plus thrombin
(P  .001).22 Notably, the incidence and type
of adverse events reported were similar in both
cohorts, suggesting that FloSeal is at least as
safe as Gelfoam.22
Efficacy and safety data for Surgiflo are similar
to that for FloSeal. Data from Woodworth et al23
found that among 30 patients (ie, 17 male, 13
female), 29 achieved hemostasis within 10 min-
utes of application of the flowable hemostat (a
96.7% success rate), with a median time to hemo-
stasis of 61 seconds. The study also noted that no
complications such as synechiae, adhesion, or
infection were reported.23
Fibrin Sealants
Fibrin sealants are absorbable dressings contain-
ing fibrinogen and thrombin that can be applied to
raw surfaces anywhere in the body cavity to cre-
ate a watertight occlusive effect. Fibrin sealants
achieve hemostasis by providing higher concen-
trations of fibrinogen and thrombin at the bleed-
ing site, thus increasing clot formation.14 These
agents—Tisseel® and Evicel®—are appropriate
for use in patients with coagulopathy who do not
have sufficient fibrinogen to form a clot,12,13 and
they are effective for control of both local and
diffuse bleeding.14
Tisseel—the first fibrin sealant approved by the
US Food and Drug Administration for use during
cardiopulmonary bypass, splenic injury repair,
colostomy closure, and colonic anastomosis—
includes human fibrinogen and thrombin from
pooled donors, as well as aprotinin to prevent
breakdown of the clot.12 Although this agent is
efficacious, its preparation is somewhat complex:
the agent comes in a two-syringe system that re-
quires stirring and warming for 20 minutes using
a device called a Fibrinotherm®.12 This required
preparation is not problematic in an elective
surgery setting, in which clinicians can frequently
predict the need for a hemostatic agent and can arepare it ahead of time; however, preparation
equirements make Tisseel an impractical choice
n the emergency setting.
Evicel incorporates human pooled plasma
hrombin and human pooled fibrinogen.13 Evicel
an be frozen for as long as two years at 18° C
0.4° F), and thawing can require up to 10 min-
tes.13 The agent can also be refrigerated for as
ong as 30 days at 2° C to 8° C (35.6° F to 46.4°
), allowing it to be quickly available with only a
ew minutes of preparation time. One important
enefit of Evicel is that it can be connected to a
ressure regulator to form a thin film over broad
leeding surface areas with no distinct bleeding
ite.13 Evicel also can be applied to control ooz-
ng from major blood vessels after bleeding has
een controlled with silk sutures.13
Research has found that fibrin sealants are
ore effective than standard topical hemostats in
chieving hemostasis.24 For example, in a pro-
pective multicenter trial, 121 patients undergoing
iver resection were randomly assigned to receive
reatment with either Crosseal (the predecessor of
vicel) or a standard topical hemostatic agent
uch as Surgicel or Gelfoam.24 The researchers
ound that the mean time to hemostasis was 282
econds in the group receiving Crosseal, whereas
68 seconds was required to control bleeding in
atients who were treated with a standard agent
P  .06). In addition, 91.4% of patients receiving
rosseal achieved hemostasis within 10 minutes,
ompared with 69.8% of patients treated with a
tandard topical hemostat (P  .003).24 Further-
ore, the postoperative complication rate was lower
n the group receiving Crosseal compared with
he standard agent cohort, at 17.2% versus
6.5%, respectively—suggesting that fibrin sealants
re more effective in achieving hemostasis.24
EW THERAPEUTIC OPTIONS:
EMOSTATIC DRESSINGS
emostatic dressings are a relatively new hemostatic
ption that was initially used in combat situations
nd is increasingly being used in civilian settings.
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November 2011 Vol 94 No 5 SCHREIBER—NEVELEFFAlthough use of these dressings outside the combat
setting currently is likely limited to large trauma
centers, their use in the prehospital setting is
increasing. This increased use necessitates that peri-
operative nurses be familiar with these products,
because these may begin appearing more frequently
in the surgical setting after preoperative trauma
management. A wide variety of hemostatic dressings
have been developed for military and civilian use.
HemCon
One effective hemostatic dressing, HemCon®, in-
cludes chitosan, a substance derived from shrimp
shells. Chitosan has mucoadhesive properties that
enable the HemCon bandage to stick to the wound,
forming a seal to stop bleeding.19 These dressings
are very stiff and nonconformable and thus can be
difficult to apply to uneven wound surfaces; how-
ever, anecdotal evidence finds that they are particu-
larly useful in treating injuries in which the skin has
been stripped off cleanly.
Use of HemCon has been studied in combat ca-
sualties in Iraq and Afghanistan.25 In one evalua-
tion, two US Army physicians provided medical
treatment in the field using HemCon dressing in 64
cases: 25 cases of chest, groin, buttock, and abdomi-
nal injuries; 35 cases of injury to extremities; and
four cases of neck or facial wounds. In 66% of
cases, HemCon bandages were used after the failure
of gauze dressings; 97% of these cases resulted in
complete bleeding cessation or improvement in he-
mostasis.25 The two reported dressing failures oc-
curred in cases of blind application in large cavita-
tional injuries in which HemCon bandages could not
be applied directly to the wound. No complications
or adverse events were reported.25
QuikClot
QuikClot®, a granular zeolite that is derived from
lava rocks, was introduced for field use in 2002.19
QuikClot works by absorbing water and concen-
trating coagulation factors. QuikClot can be
poured directly onto a wound surface, including
uneven wound surfaces, to stop bleeding.19 The
substance becomes hot via an exothermic a
S16 AORN Journaleaction—reaching up to 65° C (149° F)—and
hould not be touched by the clinician without
he use of gloves. This substance has the poten-
ial to produce burns in patients.19 In 2008, the
riginal formulation of QuikClot was discontinued
n favor of newer products such as QuikClot ACS®
nd kaolin-based products such as QuikClot Combat
auze®.19
Research on the effectiveness of QuikClot was
onducted in a retrospective analysis of self-reported
ser surveys and detailed first-hand interviews.26
he study documented 103 cases of QuikClot use:
9 by the US military in Iraq (including use by sur-
eons and medics and self-use), 20 by civilian
rauma surgeons, and 14 by civilian first responders
including police officers, emergency medical tech-
icians, firefighters, and one nonmedical layperson).
ighty-three of these cases involved application to
xternal wounds to the head, neck, chest, back, but-
ocks, pelvis, groin, abdomen, or extremities, and 20
ases involved intracorporeal use (ie, chest, abdo-
en, pelvis) by surgeons.26 The study found that
uikClot was highly effective at controlling hemor-
hage, with an overall efficacy rate of 92%. Eight
ases of hemostatic failure occurred in patients with
assive injuries for whom QuikClot was used as a
ast resort; users believed that these failures resulted
rom either the coagulopathic state of the patient
fter massive resuscitation or the inability to apply
he product directly onto the bleeding site.26 Ad-
erse reactions include mild to severe pain and dis-
omfort caused by the heat generated by QuikClot’s
xothermic reaction; three cases of burns were re-
orted, with one case requiring skin grafting. One
ase of ureteral obstruction from scar formation also
as reported.26 A new formulation of QuikClot,
alled QuikClot ACS, does not become as hot and
s more easily removed because the zeolite material
s contained in a bag that can be easily applied and
apidly removed.27 This new formulation was stud-
ed in 2007 by Arnaud et al27—data in a swine
odel showed that overall survival compared with
tandard dressing was the same for both QuikClot
nd QuikClot ACS.
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CHRISTINE S. SCHULMAN, MS, RN, CCRN
The cost of uncontrolled hemorrhage in surgical and trauma patients escalates for myriad reasons:
multiple transfusions, repeated trips to the OR, prolonged intensive care unit and hospital stays, in-
creased incidence of infections, and deaths from exsanguination. As a consequence, the primary objec-
tive of the surgical team is early and effective hemostasis by controlling surgical bleeding sites, reversing
hypothermia, transfusing appropriate coagulation products, and using a variety of topical hemostatic agents.
Continued intraoperative bleeding requires ongoing transfusion of blood and blood products.
Unfortunately, blood transfusion is an independent risk factor for increased morbidity and mortality
in a variety of critically ill and injured patient populations.1,2 Multiple mechanisms may be respon-
sible for this risk, including immune suppression, storage lesions (eg, loss of 2,3-diphosphoglycerate,
changing red blood cell morphology), and transfusion-related acute lung injury.3,4 In particular,
transfusion-related acute lung injury is considered to be the most common cause of transfusion-
related deaths, occurring in one in 5,000 red blood cell transfusions, one in 2,000 plasma-containing
infusions, and one in 400 platelet concentrate infusions.5,6 With an appreciation of the conse-
quences of blood transfusions and a solid understanding of the role of topical hemostatic agents,
the perioperative nurse plays a critical role in decreasing costs related to intraoperative bleeding
and, more importantly, reducing patient complications and deaths.
Proper selection of the appropriate hemostatic agents can greatly influence clinical outcomes. The
four general categories of topical hemostatic agents are mechanical, active, and flowable hemostats, and
fibrin sealants. Their use is determined based on the specific clinical situation and is influenced by
wound size and configuration, severity of bleeding, surgical access to the bleeding site, the patient’s
coagulation function, and whether the bleeding is the result of an initial or a repeated surgical proce-
dure. The nurse must query the surgeon at the beginning of and throughout the case about these consid-
erations, as well as inquire about which products are needed. Because circumstances can change
quickly during a surgery, frequent communication between the nurse and the surgeon regarding the
amount and site of hemorrhage and current coagulation function is essential.
Of particular concern to the clinician is the use of thrombin agents. Although they are the most com-
mon and least expensive of the topical hemostatic agents, they also carry a significant risk of complica-
tion. A delayed immunologic response to bovine factor V may manifest during subsequent surgical pro-
cedures, causing significantly disordered coagulation function.7 Furthermore, patients have been known
to develop allergic reactions after the use of human recombinant thrombins.8 There is also a risk of
viral infection despite cleansing procedures during the production of pooled human thrombin.9 The peri-
operative nurse must frequently assess the patient for any of these adverse reactions during and immedi-
ately after the surgical procedure and clearly document the administration of thrombin agents to alert
the rest of the health care team so they can continue to monitor the patient. Finally, a profound anaphy-
lactic reaction can occur with IV infusion; therefore, extreme caution must be exercised to ensure
against inadvertent intravascular administration.7-9
Another concern is the extended lead time needed to prepare some of the fibrin sealants. Al-
though this is not typically an issue with elective surgeries, it can be problematic for emergent
cases (eg, trauma, ruptured abdominal aneurysm) or for unexpected intraoperative bleeding (eg,
(continued)AORN Journal S17
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inadvertent laceration of a major vessel, postpartum hemorrhage). Tisseel® requires special equip-
ment to warm the product for at least 20 minutes before application, which makes its use impracti-
cal when a patient is bleeding profusely.10 Nurses must understand that using this agent is not ap-
propriate in such circumstances. The other fibrin sealant, Evicel®, has a water bath thaw time of
only 10 minutes. Still, because of the preparation time involved, it is important for the nurse to
speak early and often with the surgeon about the likelihood of using these particular agents.11
Today, our most current information regarding transfusion practices and the use of hemostatic agents
comes from the military experiences in the Middle East. Some of the agents used in the military theater
are successfully making their way into civilian practice; others have not translated as smoothly. Many
differences exist between military and civilian trauma scenarios, including transportation times, surgical
strategies, and the use of whole blood or 1:1:1 red blood cell:fresh frozen plasma:platelet ratios. The
results for a particular agent in a war zone may not be reproducible in the civilian surgical suite. Thus,
the civilian perioperative nurse must exercise caution when considering the results of military studies.
Although encouraging, they cannot be accepted “carte blanche” and immediately integrated into hospi-
tal policies and formularies without further study. The rapidly evolving arenas of surgical and transfu-
sion practices require that clinicians stay apprised of recent research results.
In summary, all members of the surgical team are responsible for the appropriate selection,
preparation, and application of the various topical hemostatic agents. For any one patient, they may
need to use a variety of different products. Having an easy and accessible reference guide for all
of the agents available in the blood bank, pharmacy, and operating suite will expedite application
during a situation in which time is of the essence.
Editor’s note: Tisseel is a registered trademark of Baxter International, Inc, Deerfield, IL. Evicel
is a registered trademark of Johnson & Johnson, New Brunswick, NJ.
1. Vincent JL, Baron F, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002;
288(12):1499-1507.
2. Holness L, Knippen MA, Simmons L, Lachenbruch PA. Fatalities caused by TRALI. Transfus Med Rev. 2004;
18(3):184-188.
3. Toy P, Popovsky MA, Abraham E, et al. Transfusion related acute lung injury: definition and review. Crit Care
Med. 2005;33(4):721-726.
4. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement
of a consensus panel. Transfusion. 2004;44(12):1774-1789.
5. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury.
Transfusion. 1985;25(6):573-577.
6. Goldman M, Webert KE, Arnold DM, et al. Proceedings of a consensus conference: towards an understanding of
TRALI. Transfus Med Rev. 2005;19(1):2-31.
7. Thrombin-JMI® [package insert]. Bristol, TN: King Pharmaceuticals, Inc; 2007.
8. Recothrom® [package insert]. Seattle, WA: ZymoGenetics, Inc; 2008.
9. Evithrom® [package insert]. Somerville, NJ: Ethicon, Inc; 2007.
10. Tisseel® [package insert]. Westlake Village, CA: Baxter Healthcare Corp; 2009.
11. Evicel® [package insert]. Somerville, NJ: Johnson & Johnson Wound Management; 2009.
Christine S. Schulman, MS, RN, CCRN, is a critical care clinical nurse specialist at Legacy
Health System, Portland, OR, and owner of Christine S. Schulman LLC, a consulting business for
trauma and critical care nursing in Portland, OR. Ms Schulman has no declared affiliation that
could be perceived as posing a potential conflict of interest in the publication of this article.S18 AORN Journal
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Combat gauze is a simple, thin gauze dressing im-
pregnated with kaolin, a clay that intensely activates
the clotting cascade. This dressing is easily portable
and can be packed into wounds quite effectively to
achieve a good pressure effect and stop uncontrolled
bleeding. Currently, combat gauze is included in the
first aid packets issued to all military personnel.
When studied in an animal model, combat gauze
secured hemostasis for 134.6  22 minutes and
resulted in an average survival time of 167.3  5.9
minutes, outperforming all other hemostatic agents
used in the study.28
WoundStat
WoundStat® includes a granular clay made out of
smectite; the substance can be poured into
wounds and is highly procoagulant. WoundStat
swells and thus can conform to any wound; how-
ever, removing WoundStat can be difficult and
requires debridement.
In a study conducted at the US Army Institute of
Surgical Research in San Antonio, Texas, research-
ers examined the efficacy and safety of various
granular hemostatic agents in anesthetized pigs and
found that WoundStat was the most efficacious at
achieving hemostasis and was associated with the
least amount of blood loss.29 In this arterial punch
wound model, bleeding was allowed for 45 seconds
before dressings were applied to the wounds and
compressed with a large gauze for two minutes.
Although only 10% of the wounded animals treated
with HemCon dressings achieved hemostasis after
180 minutes, 100% of animals treated with Wound-
Stat achieved stable hemostasis in the same time
frame (P  .05).29 In addition, blood loss was sig-
nificantly reduced in animals treated with Wound-
Stat compared with HemCon (P  .05).29 Although
WoundStat was more efficient in achieving hemo-
stasis, histological evidence indicates that animals
treated with WoundStat had more tissue damage
compared with animals treated with HemCon.29
Later studies further revealed that WoundStat can
embolize to the brain and lungs. Together, this sug- Fests that although WoundStat is an effective hemo-
tatic agent, future research needs to be done to in-
estigate ways to eliminate its potentially severe
dverse effects.
ONCLUSION
chieving hemostasis is a critical goal for both sur-
eons and perioperative nurses. Topical agents fre-
uently used in the surgical and trauma settings in-
lude mechanical hemostats, active hemostats,
owable hemostats, and fibrin sealants. The use of
emostatic dressings, originally developed for mili-
ary use, is increasing in hospitals and other civilian
ettings. The diversity of topical hemostatic agents
s a positive trend that offers a variety of options to
linicians; however, the growth in the number of
gents available makes it incumbent on clinicians to
nderstand their differences in order to select the
ptimal agent for a given clinical circumstance. The
onformation and extent of the wound and the
gent’s method of application, ease of use, timing
equirements, and storage requirements are some of
he critical considerations for perioperative nurses,
ho may be called on to recommend an appropriate
opical hemostat. The careful selection of a hemo-
tatic agent and knowledge about its appropriate
pplication can ensure that clinicians in the surgical
nd trauma settings can improve clinical outcomes
or their patients.
ditor’s note: Gelfoam is a registered trademark
f Pharmacia & Upjohn Company LLC, Peapack,
J. Surgifoam is a registered trademark of Ferro-
an Medical Devices A/S, Søborg, Denmark. Surgi-
el, Surgicel Nu-Knit, Evithrom, Surgiflo, and Evicel
re registered trademarks of Johnson & Johnson,
ew Brunswick, NJ. Avitene is a registered trade-
ark and Ultrafoam is a trademark of C. R. Bard,
nc, Murray Hill, NJ. Arista is a registered trade-
ark of Medafor, Inc, Minneapolis, MN. Thrombin-
MI is a registered trademark of King Pharmaceuti-
als, Inc, Bristol, TN. Recothrom is a registered
rademark of ZymoGenetics, Inc, Seattle, WA.
loSeal, Tisseel, and Fibrinotherm are registered
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November 2011 Vol 94 No 5 SCHREIBER—NEVELEFFtrademarks of Baxter International, Inc, Deerfield,
IL. HemCon is a registered trademark of HemCon
Medical Technologies, Inc, Tigard, OR. QuikClot,
QuikClot ACS, and QuikClot Combat Gauze
are registered trademarks of Z-Medica Corp,
Wallingford, CT. WoundStat is a registered trade-
mark of TraumaCure, Inc, Bethesda, MD.
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